Glyscend Inc is an innovative biotechnology company based in Baltimore, MD, specializing in the development of novel gut-targeted polymer therapies for the treatment of Type 2 Diabetes and Obesity. Their groundbreaking approach aims to replicate the benefits of metabolic surgery without the need for invasive procedures, offering a non-invasive alternative for diabetic, overweight, and obese patients. Leveraging their expertise in gastroenterology, metabolism, polymer chemistry, and drug development, Glyscend's team has contributed to the development of numerous FDA-approved therapeutic products.
With a focus on oral pill-based treatments, Glyscend's uniquely designed drugs, based on a polymer therapeutic platform, mimic the physiological effects of bariatric surgery. Their mission is to provide patients with the benefits of gastric bypass surgery and duodenal exclusion devices in a safe and accessible manner. Through their dedication to scientific research and clinical trials, Glyscend is at the forefront of revolutionizing the treatment of Type 2 Diabetes and Obesity.
Generated from the website